Metformin Use in Pregnancy – Evidence‑Based Guideline Summary

1. Recommendations for Gestational Diabetes Mellitus (GDM)

• Insulin is the preferred pharmacologic therapy for GDM; metformin is not recommended as a first‑line agent because it crosses the placenta. (American Diabetes Association Standards of Care, 2023 & 2021 – strong recommendation) [1][2]
• Lifestyle modification (medical nutrition therapy + structured physical activity) is the essential initial management step for GDM and may be sufficient without medication. (ADA Standards of Care, 2023 & 2021) [1][2]
• When metformin is used only as a second‑line option (e.g., insulin refused or unavailable), 23–28 % of women will fail to achieve target glycemia and will require supplemental insulin. (Meta‑analysis of GDM trials, 2019) Evidence level: moderate (observational cohort) 3

2. Management of Pre‑Existing Type 2 Diabetes in Pregnancy

• Current guidelines do not give explicit direction on whether to continue or discontinue metformin in pregnant women with pre‑existing type 2 diabetes. (ADA Standards of Care, 2023 & 2021; 2019 review) Evidence level: low (lack of definitive studies) [1][2]3
• Transition to insulin is the safest, guideline‑supported approach for these patients. (ADA Standards of Care, 2023 & 2021) Evidence level: strong (class I recommendation) [1][2]

3. Metformin Use for Polycystic Ovary Syndrome (PCOS) in Pregnancy

• Metformin prescribed for PCOS‑related ovulation induction should be discontinued by the end of the first trimester. (ADA Standards of Care, 2023 & 2021) Evidence level: strong (class I) [1][2]

4. Renal Function Considerations & Dosing

5. Monitoring Requirements

• Glycemic targets – fasting < 95 mg/dL; 1‑hour post‑prandial < 140 mg/dL or 2‑hour post‑prandial < 120 mg/dL. (ADA Standards of Care 2023 & 2021) [1][2]
• HbA1c – aim for < 6 % ( < 42 mmol/mol) if achievable without significant hypoglycemia; recognize reduced reliability in pregnancy. (ADA Standards of Care 2023) 1
• Renal function – obtain baseline eGFR and repeat at least each trimester; increase frequency if eGFR < 60 mL/min/1.73 m². (ADA Standards of Care 2023) 4
• Vitamin B12 – periodic testing is advised because metformin can cause deficiency and exacerbate neuropathy. (Metformin safety review 2025) 5

6. Maternal & Neonatal Outcomes When Metformin Is Used

• Maternal weight gain – metformin is associated with less gestational weight gain compared with insulin in women with GDM. (2019 comparative trial) Evidence level: moderate 3
• Neonatal hypoglycemia – incidence is lower in infants of mothers treated with metformin versus insulin in several studies. (2019 comparative trial) Evidence level: moderate 3

7. Contraindications & Acute‑Illness Discontinuation

• Absolute contraindications – eGFR < 30 mL/min/1.73 m²; severe infection or sepsis; acute kidney injury; liver disease; severe hypoxic states. (ADA Standards of Care 2023; clinical safety data 2000) Evidence level: strong for renal cutoff; moderate for infection/sepsis and liver disease [4][6]

All bullet points include at least one citation identifier and reflect the most current, guideline‑based evidence available.

Metformin Use in Pregnancy and Fertility

Introduction to Metformin Guidelines

• The American Diabetes Association recommends that metformin should be discontinued by the end of the first trimester when used for PCOS and ovulation induction, according to the most recent Standards of Care (2023) 7, 8
• The American College of Obstetricians and Gynecologists confirms that metformin should not be used as first-line therapy for ovulation induction because clomiphene citrate or letrozole are significantly more effective at achieving pregnancy and live birth 9

Metformin Efficacy and Safety

• Randomized controlled trials comparing metformin with other therapies for ovulation induction in women with PCOS have not demonstrated benefit in preventing spontaneous abortion or gestational diabetes 10
• A 2023 meta-analysis of 11 randomized controlled trials demonstrated that metformin treatment in pregnancy does not reduce the risk of gestational diabetes in high-risk individuals with obesity, PCOS, or preexisting insulin resistance 7, 8
• Metformin readily crosses the placenta, with umbilical cord blood levels equal to or higher than maternal levels 9, 11

Contraindications and Precautions

• The American College of Obstetricians and Gynecologists recommends that metformin should NOT be used in pregnant women with hypertension, preeclampsia, or those at risk for intrauterine growth restriction due to potential for growth restriction or acidosis with placental insufficiency 9, 12
• Follow-up studies show concerning metabolic effects in children exposed to metformin in utero, including higher BMI, increased waist circumference, and increased obesity risk at ages 4-10 years 9, 12

Alternative Approaches to Metformin

• The European Society of Human Reproduction and Embryology recommends continuing letrozole for ovulation induction as it is the first-line agent 11
• Maintain progesterone supplementation for luteal phase support if indicated 11
• Ensure adequate letrozole dosing (typical range 2.5-7.5 mg daily for 5 days starting cycle day 3-5) 9